Based on available data from our study population, we can estimate potential contraindications: for SGLT2i, approximately 74 patients (2.6%) had severe chronic kidney disease (eGFR <30 mL/min/1.73m2) representing a contraindication; for ACE inhibitors/ARBs, patients with hyperkalemia or bilateral renal artery stenosis would be contraindicated, though we lack systematic data on these conditions; for high-intensity statins, active liver disease would represent a contraindication, but this information was not systematically captured in our dataset. Here, ACE is linked to liver disorder.